Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Tom Powles Clear advanced filters

  • Five-year follow-up and prespecified exploratory biomarker analysis from the phase 3 KEYNOTE-426 trial show that pembrolizumab plus axitinib compared to sunitinib as first-line therapy continues to show overall and progression-free survival benefits in patients with advanced clear cell renal cell carcinoma and indicate that a T-cell-inflamed gene expression profile is predictive of response.

    • Brian I. Rini
    • Elizabeth R. Plimack
    • Thomas Powles
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 3475-3484

  • Recent data indicate that immune-checkpoint inhibitors have activity in patients with chemotherapy-refractory metastatic urothelial bladder cancer and further confirmatory trials are ongoing. Future research, including development of informative biomarker assessments, investigation of combination therapy and testing agents at earlier stages of disease is required to further explore this potential benefit.

    • Tom Powles
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 12, P: 193-194

  • Most testicular germ-cell tumours are exquisitely sensitive to platinum-based chemotherapies, but little is known about why 10% are resistant. Here, the authors explore the potential underlying mechanisms by probing the genomic landscape of platinum-resistant disease.

    • Chey Loveday
    • Kevin Litchfield
    • Clare Turnbull
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-12

  • The treatment of urological cancers is becoming increasingly complex, and, as a result, multiple specialties are required to maximize outcomes. London Cancer is an organisation with the remit of improving outcomes for patients with cancer using multidisciplinary teamwork within a large urban population. Key performance indicators will be used to assess the quality of care, and will ultimately demonstrate improved outcomes.

    • Thomas Powles
    • John Kelly
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 10, P: 609-610

  • Immune checkpoint inhibitors are associated with durable and well-tolerated responses in metastatic urothelial carcinoma. Predicting which patients respond to therapy has been challenging; however, progress has been made using programmed cell death 1 ligand 1 as a biomarker and a second generation of biomarkers, which are being assessed.

    • Tom Powles
    • Laura Morrison
    Comments & Opinion
    Nature Reviews Urology
    Volume: 15, P: 585-587

  • Although renal cell carcinoma (RCC) is increasing in incidence and is associated with a poor outcome, there is no molecular test to identify which patients will relapse and who will respond to targeted therapies. In this Review, the authors discuss the biochemical, histological and genetic characteristics of RCC, and why these characteristics have not been translated into a useful prognostic and predictive test for patients with kidney cancer.

    • Grant D. Stewart
    • Fiach C. O'Mahony
    • Dana Faratian
    Reviews
    Nature Reviews Urology
    Volume: 8, P: 255-265

  • A robust, cost-effective technique based on whole-exome sequencing data can be used to characterize immune infiltrates, relate the extent of these infiltrates to somatic changes in tumours, and enables prediction of tumour responses to immune checkpoint inhibition therapy.

    • Robert Bentham
    • Kevin Litchfield
    • Nicholas McGranahan
    Research
    Nature
    Volume: 597, P: 555-560